Profile data is unavailable for this security.
About the company
Sumitomo Pharma Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company operates through three geographical segments. The Japan segment is engaged in the manufacture, purchase, and sale of prescription drugs, purchase and sale of medical devices, undertakes development and manufacture in the field of regenerative medicine and cellular medicine, and the manufacture of pharmaceuticals, medical devices, and regenerative medicine products that have been developed through joint development in the field of regenerative medicine. This segment also provides storage and delivery service of pharmaceuticals. The North America segment is engaged in the manufacture, purchase, and sale of prescription drugs. The Asia segment is engaged in the manufacture and sale of prescription drugs (small packaging), and the import, purchase and sale of prescription drugs in Southeast Asia and Taiwan, as well as the provision and collection of information on products.
- Revenue in JPY (TTM)453.40bn
- Net income in JPY110.09bn
- Incorporated1897
- Employees3.83k
- LocationSumitomo Pharma Co Ltd2-6-8, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
- Phone+81 662035321
- Fax+81 662026028
- Websitehttps://www.sumitomo-pharma.co.jp
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sawai Group Holdings Co Ltd | 200.68bn | -1.25bn | 266.31bn | 3.31k | -- | 1.49 | 18.44 | 1.33 | -9.86 | -22.64 | 1,734.07 | 1,548.25 | 0.5445 | 1.28 | 3.40 | 60,628,400.00 | -0.3389 | -0.2327 | -0.4542 | -0.3187 | 28.89 | 32.95 | -0.6224 | -0.475 | 1.08 | -1.04 | 0.4066 | 191.65 | 6.88 | 0.7009 | -87.38 | -35.38 | 8.65 | 4.11 |
| Tsumura & Co | 189.50bn | 29.01bn | 310.56bn | 4.27k | 10.45 | 0.9878 | 7.28 | 1.64 | 387.15 | 387.15 | 2,524.84 | 4,095.99 | 0.374 | 0.7106 | 2.41 | 44,357,680.00 | 6.01 | 5.53 | 8.06 | 6.85 | 47.60 | 49.39 | 16.06 | 14.50 | 1.45 | -- | 0.2856 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Nippon Shinyaku Co Ltd | 166.05bn | 29.85bn | 351.26bn | 2.24k | 11.28 | 1.19 | 9.70 | 2.12 | 443.17 | 443.17 | 2,465.26 | 4,211.80 | 0.5421 | 1.17 | 3.19 | 74,028,980.00 | 9.75 | 10.89 | 10.81 | 12.74 | 67.29 | 63.93 | 17.98 | 17.67 | 4.04 | -- | 0.0089 | 30.58 | 8.08 | 6.56 | 25.94 | 14.06 | 80.48 | 7.59 |
| Hisamitsu Pharmaceutical Co Inc | 159.27bn | 19.99bn | 465.27bn | 2.80k | 22.35 | 1.61 | 16.90 | 2.92 | 276.99 | 276.99 | 2,208.13 | 3,837.32 | 0.4704 | 2.64 | 3.42 | 56,901,390.00 | 6.04 | 4.34 | 7.25 | 4.99 | 59.05 | 57.83 | 12.84 | 10.32 | 3.28 | -- | 0.0086 | 50.29 | 10.09 | 2.04 | 55.76 | 3.08 | 29.89 | 0.7127 |
| Santen Pharmaceutical Co Ltd | 287.99bn | 30.60bn | 551.89bn | 3.85k | 18.61 | 1.94 | 11.33 | 1.92 | 92.03 | 92.03 | 865.27 | 880.97 | 0.7205 | 2.26 | 4.18 | 74,823,070.00 | 7.63 | 3.94 | 9.43 | 4.93 | 56.89 | 58.97 | 10.59 | 6.01 | 1.89 | -- | 0.1757 | 71.86 | -0.6494 | 4.43 | 36.09 | 8.94 | 3.61 | 5.92 |
| Rohto Pharmaceutical Co Ltd | 335.80bn | 34.48bn | 580.76bn | 9.14k | 16.58 | 1.93 | 11.16 | 1.73 | 148.28 | 148.28 | 1,444.67 | 1,272.14 | 0.7768 | 2.32 | 4.55 | 36,723,640.00 | 8.02 | 8.59 | 11.20 | 11.70 | 56.06 | 57.78 | 10.33 | 10.57 | 1.43 | -- | 0.1452 | 21.12 | 13.95 | 10.38 | 0.2263 | 15.01 | 10.42 | 22.59 |
| Sumitomo Pharma Co Ltd | 453.40bn | 110.09bn | 1.18tn | 3.83k | 10.72 | 4.08 | 8.97 | 2.61 | 277.11 | 277.11 | 1,141.22 | 727.28 | 0.5438 | 1.95 | 3.99 | 118,318,100.00 | 13.20 | -5.49 | 23.02 | -8.49 | 59.24 | 67.88 | 24.28 | -13.24 | 1.01 | 4.17 | 0.4726 | -- | 26.79 | -3.75 | 107.50 | -10.32 | -0.4856 | -- |
| Ono Pharmaceutical Co Ltd | 509.35bn | 62.40bn | 1.27tn | 4.29k | 19.17 | 1.42 | 12.77 | 2.49 | 132.76 | 132.76 | 1,084.01 | 1,786.88 | 0.4702 | 2.14 | 3.38 | 118,811,500.00 | 5.77 | 10.78 | 6.61 | 12.37 | 69.79 | 73.23 | 12.27 | 21.23 | 2.56 | 125.26 | 0.1283 | 36.33 | -3.14 | 10.73 | -60.89 | -3.47 | -18.66 | 12.20 |
| Kyowa Kirin Co Ltd | 496.83bn | 67.04bn | 1.36tn | 5.67k | 20.24 | 1.52 | 14.62 | 2.74 | 128.07 | 128.07 | 949.13 | 1,706.50 | 0.4568 | 1.82 | 2.99 | -- | 6.16 | 6.40 | 7.33 | 7.37 | 74.25 | 74.99 | 13.49 | 14.37 | 2.35 | -- | -- | 46.19 | 0.2559 | 9.31 | 11.98 | 7.35 | 19.80 | 7.10 |
| Eisai Co Ltd | 808.19bn | 42.76bn | 1.46tn | 13.51k | 32.95 | 1.58 | 17.41 | 1.80 | 151.67 | 151.67 | 2,866.61 | 3,153.46 | 0.5537 | 0.7996 | 3.33 | 59,839,040.00 | 3.04 | 3.81 | 4.22 | 5.14 | 77.75 | 77.47 | 5.48 | 6.44 | 1.54 | -- | 0.2015 | 98.01 | 6.42 | 2.56 | 9.49 | -17.54 | -14.48 | 0.00 |
| Shionogi & Co Ltd | 465.35bn | 194.86bn | 3.07tn | 4.96k | 15.07 | 1.94 | 14.22 | 6.60 | 228.94 | 228.94 | 546.70 | 1,779.33 | 0.2869 | 0.8648 | 2.76 | 93,915,640.00 | 11.98 | 12.17 | 13.13 | 13.74 | 84.50 | 84.91 | 41.78 | 38.30 | 5.21 | -- | 0.0148 | 27.87 | 0.7325 | 5.62 | 5.19 | 6.88 | 34.66 | 12.30 |
| Astellas Pharma Inc | 2.06tn | 322.91bn | 4.40tn | 13.64k | 13.54 | 2.47 | 8.55 | 2.14 | 179.57 | 179.57 | 1,145.43 | 984.21 | 0.5841 | 1.27 | 2.90 | 151,038,200.00 | 9.15 | 3.05 | 14.11 | 4.45 | 81.00 | 81.15 | 15.67 | 5.42 | 0.839 | 41.32 | 0.2913 | 131.42 | 19.25 | 8.01 | 197.72 | -23.64 | -5.94 | 13.09 |
Data as of Feb 18 2026. Currency figures normalised to Sumitomo Pharma Co Ltd's reporting currency: Japanese Yen JPY
12.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 05 Feb 2026 | 14.62m | 3.68% |
| Amova Asset Management Co., Ltd.as of 06 Feb 2026 | 7.35m | 1.85% |
| Daiwa Asset Management Co. Ltd.as of 30 Jan 2026 | 6.86m | 1.73% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 6.13m | 1.54% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Feb 2026 | 4.85m | 1.22% |
| Norges Bank Investment Managementas of 30 Sep 2025 | 2.85m | 0.72% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 2.81m | 0.71% |
| Arcus Investment Ltd.as of 30 Sep 2024 | 1.89m | 0.47% |
| BlackRock Japan Co. Ltd.as of 05 Feb 2026 | 1.57m | 0.39% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2024 | 1.26m | 0.32% |
More ▼
Data from 30 Sep 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
